Quantum Genomics’ brain-targeting blood pressure drug meets phase 2b endpoints
November 13, 2018
By Neozene

Quantum Genomics’ blood pressure drug firibastat, an inhibitor that targets aminopeptidase A in the brain, met its primary endpoint in a phase 2b study—which the company says paves the way for a wider phase 3 trial in more resistant hypertension. Firibastat lowered systolic automatic office blood pressure, or AOBP, by 9.7 mm Hg compared to baseline readings in patients with arterial hypertension, while lowering diastolic pressure by 4.3 mm Hg. Both endpoints reached P values of less than 0.0001. “A minimum decrease of 7 mmHg in systolic AOBP represents a

Read More

Mylan and Pfizer report new issues affecting some EpiPens that can delay treatment
November 7, 2018
By Neozene

More than a month after Mylan and Pfizer reported to Health Canada that there are new issues affecting some EpiPens, the companies and the FDA notified U.S. healthcare providers of the problem, which can delay treatment when the pens are needed. Mylan, Pfizer and the FDA reported on Friday that some pens and their authorized generic versions may not easily slide out of their carrier tube and so could delay use of the pens. They said that in a very small number of cases, labels were not fully adhered to

Read More

Studies use retinal scans to potentially identify earlier signs of Alzheimer’s disease
October 30, 2018
By Neozene

Two studies showed that noninvasive eye scans measuring the thickness of the retina can provide a window into the early signs of Alzheimer’s disease, with the goal of providing a quick, inexpensive test for identifying those at a higher risk. By using optical coherence tomography angiography, or OCT scans, researchers observed cross sections of patients’ retinas, visualizing the changes seen in its smallest blood vessels. They believe that the deterioration of the retina may mirror the disease’s progression in the brain, conveyed across the optic nerve. The researchers were able

Read More